Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
89.14
-1.17 (-1.30%)
Mar 20, 2026, 1:58 PM EDT - Market open

Rhythm Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-196.54-260.6-184.68-181.12-69.61
Depreciation & Amortization
1.341.561.761.671.16
Stock-Based Compensation
66.8239.6832.5519.8320.8
Other Adjustments
13.6894.99.43.6-100.25
Change in Receivables
-7.57-3.65-8.64-5.2-1.25
Changes in Inventories
-7.47-10.12-5.71-2.81-0.01
Changes in Accounts Payable
21.8921.9214.771.5418.31
Changes in Unearned Revenue
-1.09--0.15-6.61-
Changes in Other Operating Activities
-6.722.424.53-4.34-15.15
Operating Cash Flow
-115.68-113.88-136.16-173.43-146
Capital Expenditures
-0.95--0.05-0.28-0.43
Purchases of Intangible Assets
-40-40.5-5.67-4-5
Purchases of Investments
-348.67-268.31-354.92-251.94-524.97
Proceeds from Sale of Investments
252.47260.64354.97284.25361.25
Other Investing Activities
----107
Investing Cash Flow
-137.15-48.17-5.6728.03-62.16
Long-Term Debt Issued
--24.3772.34-
Long-Term Debt Repaid
-19.92-12.9-7.4--
Net Long-Term Debt Issued (Repaid)
-19.92-12.916.9772.34-
Issuance of Common Stock
237.8856.3957.4141.49166.48
Net Common Stock Issued (Repurchased)
237.8856.3957.4141.49166.48
Issuance of Preferred Stock
-138.85---
Net Preferred Stock Issued (Repurchased)
-138.85---
Other Financing Activities
-8.9---
Financing Cash Flow
217.96191.2474.37213.83166.48
Effect of Exchange Rate Changes on Cash and Cash Equivalents
0.090-0.14--
Net Cash Flow
-34.7829.19-67.668.43-41.68
Free Cash Flow
-116.63-113.88-136.2-173.71-146.44
FCF Margin
-61.46%-87.51%-175.91%-734.87%-4642.90%
Free Cash Flow Per Share
-1.79-1.87-2.36-3.33-2.95
Levered Free Cash Flow
-214.85-261.69-152.55-119.6-65.74
Unlevered Free Cash Flow
-185.52-250.07-169.76-189.98-166.19
Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q